论文部分内容阅读
目的:探讨应用双歧杆菌三联活菌胶囊联合莫沙必利治疗慢性功能性便秘的疗效及机制。方法:选择从2009年2月到2012年2月期间在瑞安市中医院收治的符合罗马Ⅲ慢性便秘诊断标准的慢性功能性便秘64例,将所选患者随机分为两组,每组各32例,两组患者均予以莫沙比利5mg/次,每天3次,餐前0.5h服用。治疗组在此基础上予以双歧杆菌胶囊0.42g/次,每天3次,2组患者均连用4周。观察两组患者治疗前后血浆SP、NO水平的变化。观察两组临床疗效及治疗过程中不良反应的发生情况。结果:经过4周治疗后,2组患者血浆SP水平较治疗前明显上升(P<0.05),且治疗组患者上升更为显著,而血浆NO水平相比治疗前均明显下降(P<0.05),且治疗组下降程度更为显著(P<0.05),治疗组患者有22例显效,总有效率为93.8%,而对照组患者有16例显效,总有效率为81.3%。两组患者疗效相比有显著差异性(P<0.05),治疗组患者在治疗期间出现1例稀便,1例腹痛;而对照组患者则出现3例稀便,2例腹痛,然而2组患者不良反应症状均较轻,在治疗中未给予处理而症状自行消失。随访3个月后发现治疗组患者有1例复发,而对照组有4例出现复发。结论:双歧杆菌三联活菌胶囊联合莫沙必利治疗慢性功能便秘能明显改善患者血浆SP和NO的水平,疗效确切,复发率低,安全性较好;值得在临床上推广应用。
Objective: To investigate the efficacy and mechanism of Bifidobacterium triple active viable capsule combined with mosapride in the treatment of chronic functional constipation. Methods: Sixty-four cases of chronic functional constipation who met the diagnostic criteria of Rome Ⅲ chronic constipation admitted from Ruian Hospital of Traditional Chinese Medicine from February 2009 to February 2012 were selected. The patients were randomly divided into two groups of 32 For example, both groups were given mosapride 5mg / time, 3 times a day, taking 0.5h before meals. The treatment group was given Bifidobacterium capsules 0.42g / time on this basis, 3 times a day, two groups of patients were used for 4 weeks. The changes of plasma SP and NO levels in two groups before and after treatment were observed. The clinical efficacy and the incidence of adverse reactions in the two groups were observed. Results: After 4 weeks of treatment, the level of plasma SP in two groups increased significantly (P <0.05), and the level of SP in treatment group increased more significantly than that before treatment (P <0.05) (P <0.05). The treatment group had 22 cases markedly effective, the total effective rate was 93.8%, while the control group had 16 cases markedly effective, the total effective rate was 81.3%. There was significant difference between the two groups (P <0.05). One case of stool loss and one case of abdominal pain were found in the treatment group, while three cases of loose stool and two cases of abdominal pain appeared in the control group. However, Patients with adverse reactions were mild symptoms, did not give treatment in the treatment of symptoms disappear. Three months after follow-up, 1 patient recurred in the treatment group and 4 in the control group. Conclusion: Bifidobacterium triple viable capsule combined with mosapride in the treatment of chronic functional constipation can significantly improve the level of plasma SP and NO in patients with definite curative effect, low recurrence rate and good safety. It is worth popularizing in clinical application.